US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telomir Pharmaceuticals

1.21

-0.0593-4.67%

Volume:192.46K

Turnover:236.14K

Market Cap:36.03M

PE:-2.92

High:1.29

Open:1.29

Low:1.19

Close:1.27

Loading ...

Overview Company News Filings

Telomir Pharmaceuticals Reports Positive Preclinical Data

Telomir Pharmaceuticals Inc - Telomir-1 Significantly Increased Cell Viability - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals Reveals Promising Preclinical Data for Telomir-1 in Combatting Rapid Aging in Progeria Patients

Telomir Pharmaceuticals Announces Promising Preclinical Results

Telomir Pharmaceuticals Inc - Telomir-1 Advancing Toward Ind Submission by Year-End - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals: Telomir-1 Shows Dose-Dependent Restoration of Neurological, Liver & Kidney Function in Wilson’s Disease Animal Model

THOMSON REUTERS

Telomir Pharmaceuticals Unveils Promising Preclinical Results for Telomir-1 in Treating Wilson's Disease

Telomir Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership: Alan Weichselbaum, Chief Financial Officer

Telomir Pharmaceuticals-New Data From Preclinical Study of Its Lead Compound, Telomir-1, in Validated Animal Model of Werner Syndrome

THOMSON REUTERS

Telomir Pharmaceuticals- Announces Telomir-1 Resets Epigenetic Clock, Reverses DNA Methylation - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals Unveils Promising Preclinical Study Results of Telomir-1 Showing Potential to Reverse Aging Effects in Werner Syndrome Model

Telomir Pharmaceuticals Announces Upcoming Clinical Trials for Telomir-1, Aiming to Tackle Aging and Rare Diseases

Telomir Pharmaceuticals Announces Promising Preclinical Results for Telomir-1 in Treating Age-Related Macular Degeneration

BRIEF-Telomir Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Telomir Pharmaceuticals - SEC Filing

Telomir Pharmaceuticals Appoints New Chief Financial Officer

Telomir Pharmaceuticals Inc - Appoints Alan Weichselbaum as CFO - SEC Filing

THOMSON REUTERS

Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale

MT Newswires Live

Telomir Pharmaceuticals announces $3M in equity financing

Telomir Pharmaceuticals Secures $3M Equity Financing Boost

Telomir Pharmaceuticals Secures $3M Through Equity Sale at Premium, Following Prior $1M Investment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TELO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TELO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","market":"US","secType":"STK","nameCN":"Telomir Pharmaceuticals","latestPrice":1.2107,"timestamp":1751477685907,"preClose":1.27,"halted":0,"volume":192460,"delay":0,"floatShares":17618248,"shares":29762671,"eps":-0.414741,"marketStatus":"Trading","change":-0.0593,"latestTime":"07-02 13:35:55 EDT","open":1.29,"high":1.29,"low":1.19,"amount":236138.02716000003,"amplitude":0.07874,"askPrice":1.22,"askSize":100,"bidPrice":1.21,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.414741,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751486400000},"marketStatusCode":2,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":1.27,"preHourTrading":{"tag":"盘前","latestPrice":1.2495,"preClose":1.27,"latestTime":"08:54 EDT","volume":929,"amount":1169.5549813,"timestamp":1751460896846},"postHourTrading":{"tag":"盘后","latestPrice":1.27,"preClose":1.27,"latestTime":"19:41 EDT","volume":548,"amount":700.5496,"timestamp":1751413308343},"volumeRatio":0.362913},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TELO\",,,,,undefined,":{"symbol":"TELO","floatShares":17618248,"roa":"-391.62%","roe":"-872.57%","lyrEps":-0.559686,"volumeRatio":0.362913,"shares":29762671,"dividePrice":0,"high":1.29,"amplitude":0.07874,"preClose":1.27,"low":1.19,"week52Low":1.185,"pbRate":"-223.66","week52High":8.4,"institutionHeld":0,"latestPrice":1.2107,"committee":0.95122,"eps":-0.414741,"divideRate":0,"volume":192460,"delay":0,"ttmEps":-0.414741,"open":1.29,"prevYearClose":4.12,"prevWeekClose":1.53,"prevMonthClose":1.25,"prevQuarterClose":1.25,"fiveDayClose":1.78,"twentyDayClose":2.04,"sixtyDayClose":2.93},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TELO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544990333","title":"Telomir Pharmaceuticals Reports Positive Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2544990333","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544990333?lang=en_us&edition=fundamental","pubTime":"2025-06-18 21:53","pubTimestamp":1750254789,"startTime":"0","endTime":"0","summary":"An update from Telomir Pharmaceuticals, Inc. ( ($TELO) ) is now available. On June 18, 2025, Telomir Pharmaceuticals announced positive preclinical...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-reports-positive-preclinical-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-reports-positive-preclinical-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2544970254","title":"Telomir Pharmaceuticals Inc - Telomir-1 Significantly Increased Cell Viability - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2544970254","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544970254?lang=en_us&edition=fundamental","pubTime":"2025-06-18 21:21","pubTimestamp":1750252887,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nFWN3SL0KU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2544701529","title":"Telomir Pharmaceuticals Reveals Promising Preclinical Data for Telomir-1 in Combatting Rapid Aging in Progeria Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2544701529","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544701529?lang=en_us&edition=fundamental","pubTime":"2025-06-18 21:15","pubTimestamp":1750252519,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced new preclinical data regarding its lead candidate, Telomir-1, which shows promising results in preventing cellular aging in human progeria cell lines. The study utilized cell lines from the Progeria Research Foundation and demonstrated that Telomir-1 targets key mechanisms of disease progression in progeria, including oxidative stress, metal toxicity, and mitochondrial instability. These findings build on previous studies in zebrafish and nematodes and suggest potential applications for Telomir-1 in treating other age-related diseases. The company plans to engage with the U.S. Food and Drug Administration to explore regulatory pathways and is evaluating multiple rare disease indications for initial clinical development. The results have been presented and indicate a significant step toward clinical translation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL2B9mtG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2542580255","title":"Telomir Pharmaceuticals Announces Promising Preclinical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2542580255","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542580255?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:59","pubTimestamp":1749650342,"startTime":"0","endTime":"0","summary":"The latest update is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). On June 11, 2025, Telomir Pharmaceuticals announced promising preclinical ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-announces-promising-preclinical-results-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-announces-promising-preclinical-results-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2542758745","title":"Telomir Pharmaceuticals Inc - Telomir-1 Advancing Toward Ind Submission by Year-End - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2542758745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542758745?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:34","pubTimestamp":1749648889,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nFWN3SE0CC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2542587456","title":"Telomir Pharmaceuticals: Telomir-1 Shows Dose-Dependent Restoration of Neurological, Liver & Kidney Function in Wilson’s Disease Animal Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2542587456","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542587456?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:34","pubTimestamp":1749648889,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nFWN3SE0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2542871475","title":"Telomir Pharmaceuticals Unveils Promising Preclinical Results for Telomir-1 in Treating Wilson's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2542871475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542871475?lang=en_us&edition=fundamental","pubTime":"2025-06-11 21:31","pubTimestamp":1749648686,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc.  has announced promising preclinical data for its lead small molecule candidate, Telomir-1, in the treatment of Wilson's disease. The study demonstrated that Telomir-1 significantly improved neurological, behavioral, liver, and kidney functions in a genetically relevant animal model of the disease. Results showed a dose-dependent reversal of neurological dysfunction, organ damage, copper accumulation, and mortality. Additionally, Telomir-1 normalized critical liver health markers, indicating potential protection of liver function. These findings justify further development towards human clinical trials, which are planned for the first half of 2026. The company aims to submit an Investigational New Drug  application by the end of the year, advancing Telomir-1 as a potential disease-modifying treatment for rare disorders involving copper dysregulation. Results of the preclinical study were presented on June 11, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDLzbD9m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2542723316","title":"Telomir Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership: Alan Weichselbaum, Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2542723316","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542723316?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:13","pubTimestamp":1749554012,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has filed an initial statement of beneficial ownership. The document lists Alan Weichselbaum as the beneficial owner, serving as the Chief Financial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL8rfxTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2541402024","title":"Telomir Pharmaceuticals-New Data From Preclinical Study of Its Lead Compound, Telomir-1, in Validated Animal Model of Werner Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2541402024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541402024?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:22","pubTimestamp":1749126165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S807G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2541241020","title":"Telomir Pharmaceuticals- Announces Telomir-1 Resets Epigenetic Clock, Reverses DNA Methylation - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2541241020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541241020?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:22","pubTimestamp":1749126165,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S807G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2541027722","title":"Telomir Pharmaceuticals Unveils Promising Preclinical Study Results of Telomir-1 Showing Potential to Reverse Aging Effects in Werner Syndrome Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2541027722","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541027722?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:01","pubTimestamp":1749124874,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Unveils Promising Preclinical Study Results of Telomir-1 Showing Potential to Reverse Aging Effects in Werner Syndrome Model. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLcb9xqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2540760747","title":"Telomir Pharmaceuticals Announces Upcoming Clinical Trials for Telomir-1, Aiming to Tackle Aging and Rare Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760747?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:01","pubTimestamp":1748865690,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc.  has announced its participation in the upcoming BIO International Convention 2025 in Boston, Massachusetts, scheduled from June 16-19, 2025. The company plans to engage in BIO One-on-One Partnering meetings to explore potential licensing, strategic collaborations, and M&A opportunities. Additionally, Telomir provided updates on its lead candidate, Telomir-1, which is designed to elongate telomeres, regenerate cells, and address key drivers of biological aging. The company is preparing for an Investigational New Drug  submission by the end of the year and anticipates initiating first-in-human clinical trials in the first half of 2026. Telomir also reported preclinical progress in areas such as retinal regeneration, lifespan extension, Type 2 diabetes reversal, and anti-cancer effects. Furthermore, Telomir is launching a rare disease development initiative targeting conditions like Werner's syndrome, Wilson's disease, Progeria, and dysphonia.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL2w0B8x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO","BK4007"],"gpt_icon":0},{"id":"2539257705","title":"Telomir Pharmaceuticals Announces Promising Preclinical Results for Telomir-1 in Treating Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2539257705","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539257705?lang=en_us&edition=fundamental","pubTime":"2025-05-29 20:01","pubTimestamp":1748520064,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has announced promising preclinical results from its ongoing development of Telomir-1, an investigational oral small molecule candidate for treating age-related macular degeneration . The study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which reflects key features of dry AMD and geographic atrophy observed in humans. Over a 14-day period, Telomir-1 was administered orally to 18-month-old animals. The treatment resulted in improved central vision response and motion detection, regeneration of several critical retinal layers, and a reduction in oxidative stress. Notably, untreated animals experienced a 15% mortality rate, while no mortality was observed in the Telomir-1 treated groups. These findings are considered a significant preclinical milestone that supports the continued advancement of Telomir-1 towards an Investigational New Drug  submission.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL9WDV7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2537520249","title":"BRIEF-Telomir Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Telomir Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537520249","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537520249?lang=en_us&edition=fundamental","pubTime":"2025-05-22 06:42","pubTimestamp":1747867341,"startTime":"0","endTime":"0","summary":"BRIEF-Telomir Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Telomir Pharmaceuticals - SEC FilingTelomir Pharmaceuticals Inc TELO.O:TELOMIR PHARMACEUTICALS INC - MICHELLE YANEZ STEPS DOWN AS CFO OF TELOMIR PHARMACEUTICALS - SEC FILINGTELOMIR PHARMACEUTICALS INC - APPOINTS ALAN WEICHSELBAUM AS CFO - SEC FILINGSource text: [ID:n0001641172-25-011938]Further company coverage: TELO.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT2WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TELO"],"gpt_icon":0},{"id":"2537525749","title":"Telomir Pharmaceuticals Appoints New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537525749","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537525749?lang=en_us&edition=fundamental","pubTime":"2025-05-22 05:49","pubTimestamp":1747864151,"startTime":"0","endTime":"0","summary":"The latest update is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). On May 16, 2025, Telomir Pharmaceuticals, Inc. announced the mutual resign...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-new-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-new-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2537954192","title":"Telomir Pharmaceuticals Inc - Appoints Alan Weichselbaum as CFO - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537954192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537954192?lang=en_us&edition=fundamental","pubTime":"2025-05-22 05:26","pubTimestamp":1747862784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT2WO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TELO"],"gpt_icon":0},{"id":"2537939154","title":"Telomir Pharmaceuticals Obtains $3 Million in Straight Equity Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2537939154","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537939154?lang=en_us&edition=fundamental","pubTime":"2025-05-21 22:07","pubTimestamp":1747836462,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals  said Wednesday it has obtained $3 million in equity financing through a direct investment from its largest shareholder The Bayshore Trust.The deal, which involved the purchase of 1 million Telomir restricted shares at $3 apiece, was structured as a straight stock transaction with no warrants, discounts, and convertible features, the company said.Telomir said the investment will fund its upcoming submission of its investigational new drug application for a rare disease indication.Shares of the company fell 3.1% in recent trading.Price: 2.22, Change: -0.07, Percent Change: -3.10","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4215","TELO","BK4007","BK4588","EQR","BK4585"],"gpt_icon":0},{"id":"2537239935","title":"Telomir Pharmaceuticals announces $3M in equity financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537239935","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537239935?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:21","pubTimestamp":1747833670,"startTime":"0","endTime":"0","summary":"Telomir has secured $3M in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder. The transaction ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-announces-3m-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/telomir-pharmaceuticals-announces-3m-in-equity-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4512","LU1894683348.USD","LU1894683264.USD","BK4007","BK4206","LU0683600562.USD","MMM","LU1093756325.SGD","TELO","SG9999002224.SGD","BK4585","LU1093756168.USD","BK4588","LU0787776722.HKD","BK4533","SG9999002232.USD"],"gpt_icon":0},{"id":"2537354269","title":"Telomir Pharmaceuticals Secures $3M Equity Financing Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2537354269","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537354269?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:18","pubTimestamp":1747833497,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals, Inc. ( ($TELO) ) has provided an announcement. On May 19, 2025, Telomir Pharmaceuticals secured $3 million in equity finan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-secures-3m-equity-financing-boost?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-secures-3m-equity-financing-boost?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0787776722.HKD","LU1093756168.USD","LU0683600562.USD","LU1894683264.USD","BK4007","BK4206","MMM","SG9999002224.SGD","BK4533","LU1093756325.SGD","BK4588","BK4534","BK4512","EQR","LU1894683348.USD","BK4215","SG9999002232.USD","TELO"],"gpt_icon":0},{"id":"2537933802","title":"Telomir Pharmaceuticals Secures $3M Through Equity Sale at Premium, Following Prior $1M Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933802","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537933802?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:46","pubTimestamp":1747831571,"startTime":"0","endTime":"0","summary":"Telomir Pharmaceuticals Inc. has completed a $3 million equity financing through a direct investment by The Bayshore Trust, issuing 1 million restricted shares at $3.00 per share, an 18% premium to the closing price on May 19, 2025. Previously, on December 9, 2024, a $1 million equity investment was made by The Starwood Trust, with shares priced at $7.00 each. Both trusts are affiliated with the company's largest shareholder.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2025, and is solely responsible f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDLc1xZXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TELO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TELO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"TELO","fiscalQuarterEnding":"2025/03","expectedEps":-0.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2025-02-04","symbol":"TELO","fiscalQuarterEnding":"2024/12","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2024-11-12","symbol":"TELO","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TELO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TELO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TELO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TELO","date":"2025-07-01","current":-2.986316,"percent":1,"low":-83.265127,"twenty":-10.413329,"median":-7.290926,"eighty":-5.407572,"high":-2.986316,"avg":-12.021191,"sd":14.177941,"marketCap":37203338},"quantilePoints":[{"date":"2024-02-16","current":-56.39638,"twenty":-61.770129,"median":-49.049457,"eighty":-41.982417,"marketCap":238655100},{"date":"2024-02-23","current":-62.343889,"twenty":-63.029602,"median":-60.594622,"eighty":-46.922348,"marketCap":263823442},{"date":"2024-03-01","current":-63.46342,"twenty":-63.421438,"median":-62.588787,"eighty":-53.457611,"marketCap":268561012},{"date":"2024-03-08","current":-60.874505,"twenty":-63.351467,"median":-62.553802,"eighty":-58.915325,"marketCap":257605381},{"date":"2024-03-15","current":-45.550923,"twenty":-63.197532,"median":-61.749139,"eighty":-48.657621,"marketCap":192759889},{"date":"2024-03-22","current":-47.510102,"twenty":-63.029602,"median":-60.594622,"eighty":-45.928765,"marketCap":201050637},{"date":"2024-03-28","current":-35.580099,"twenty":-62.973626,"median":-56.39638,"eighty":-42.472212,"marketCap":150565904},{"date":"2024-04-05","current":-16.558518,"twenty":-62.833684,"median":-48.559663,"eighty":-36.881554,"marketCap":216450701},{"date":"2024-04-12","current":-18.574281,"twenty":-62.595784,"median":-46.390571,"eighty":-17.881143,"marketCap":242800474},{"date":"2024-04-19","current":-18.007992,"twenty":-62.469837,"median":-45.480952,"eighty":-18.234508,"marketCap":235398021},{"date":"2024-04-26","current":-15.402836,"twenty":-62.287913,"median":-41.632564,"eighty":-16.272973,"marketCap":201343774},{"date":"2024-05-03","current":-15.493668,"twenty":-61.8401,"median":-38.868721,"eighty":-15.530047,"marketCap":202531127},{"date":"2024-05-10","current":-14.814122,"twenty":-61.126399,"median":-34.985348,"eighty":-15.280653,"marketCap":193648183},{"date":"2024-05-17","current":-9.713938,"twenty":-60.762552,"median":-20.205194,"eighty":-14.460757,"marketCap":183044909},{"date":"2024-05-24","current":-9.899514,"twenty":-60.034856,"median":-18.959358,"eighty":-13.282876,"marketCap":186541828},{"date":"2024-05-31","current":-9.506677,"twenty":-58.635442,"median":-18.087272,"eighty":-12.474215,"marketCap":179139374},{"date":"2024-06-07","current":-8.846709,"twenty":-55.220872,"median":-16.988785,"eighty":-10.175947,"marketCap":166703252},{"date":"2024-06-14","current":-8.642433,"twenty":-50.224965,"median":-16.082609,"eighty":-9.764378,"marketCap":162853977},{"date":"2024-06-21","current":-8.249595,"twenty":-49.049457,"median":-15.652229,"eighty":-9.506677,"marketCap":155451523},{"date":"2024-06-28","current":-7.558201,"twenty":-48.069868,"median":-15.505107,"eighty":-8.846709,"marketCap":142423205},{"date":"2024-07-05","current":-6.803952,"twenty":-47.622055,"median":-15.431264,"eighty":-8.793283,"marketCap":128210494},{"date":"2024-07-12","current":-6.489682,"twenty":-46.614477,"median":-14.995334,"eighty":-8.611006,"marketCap":122288531},{"date":"2024-07-19","current":-5.892568,"twenty":-46.222641,"median":-14.134574,"eighty":-8.227596,"marketCap":111036802},{"date":"2024-07-26","current":-6.096844,"twenty":-45.67687,"median":-13.432376,"eighty":-7.822188,"marketCap":114886078},{"date":"2024-08-02","current":-5.248314,"twenty":-45.438969,"median":-12.639572,"eighty":-6.797667,"marketCap":98896778},{"date":"2024-08-09","current":-6.741098,"twenty":-44.067543,"median":-12.367753,"eighty":-6.690814,"marketCap":127026102},{"date":"2024-08-16","current":-6.303607,"twenty":-42.052388,"median":-10.284417,"eighty":-6.64996,"marketCap":118143157},{"date":"2024-08-23","current":-8.29422,"twenty":-40.401079,"median":-9.899514,"eighty":-6.678244,"marketCap":155451523},{"date":"2024-08-30","current":-8.278421,"twenty":-39.141606,"median":-9.736016,"eighty":-6.690814,"marketCap":155155425},{"date":"2024-09-06","current":-8.136234,"twenty":-38.861724,"median":-9.674022,"eighty":-6.712813,"marketCap":152490542},{"date":"2024-09-13","current":-9.589698,"twenty":-36.881554,"median":-9.506677,"eighty":-6.734812,"marketCap":179731570},{"date":"2024-09-20","current":-12.386034,"twenty":-35.223248,"median":-9.49882,"eighty":-6.759954,"marketCap":232140941},{"date":"2024-09-27","current":-10.774586,"twenty":-34.271647,"median":-9.637093,"eighty":-6.791381,"marketCap":201938931},{"date":"2024-10-04","current":-8.578593,"twenty":-25.750182,"median":-9.548188,"eighty":-6.888805,"marketCap":160781290},{"date":"2024-10-11","current":-8.009846,"twenty":-20.168951,"median":-9.479108,"eighty":-7.001943,"marketCap":150121756},{"date":"2024-10-18","current":-7.425301,"twenty":-19.534707,"median":-9.44751,"eighty":-7.071981,"marketCap":139166125},{"date":"2024-10-25","current":-7.01454,"twenty":-19.059025,"median":-9.384317,"eighty":-6.903527,"marketCap":131467574},{"date":"2024-11-01","current":-6.714368,"twenty":-18.728312,"median":-9.226332,"eighty":-6.834437,"marketCap":125841709},{"date":"2024-11-08","current":-6.666973,"twenty":-18.282076,"median":-8.941959,"eighty":-6.759954,"marketCap":124953415},{"date":"2024-11-15","current":-4.809979,"twenty":-18.039704,"median":-8.846709,"eighty":-6.708049,"marketCap":110444606},{"date":"2024-11-22","current":-5.467643,"twenty":-17.654627,"median":-8.799568,"eighty":-6.673736,"marketCap":125545611},{"date":"2024-11-29","current":-5.132363,"twenty":-17.074838,"median":-8.768141,"eighty":-6.632216,"marketCap":117847059},{"date":"2024-12-06","current":-8.407791,"twenty":-16.522185,"median":-8.642433,"eighty":-6.569924,"marketCap":193055987},{"date":"2024-12-13","current":-6.737953,"twenty":-16.313655,"median":-8.594391,"eighty":-6.600602,"marketCap":154713889},{"date":"2024-12-20","current":-6.712037,"twenty":-15.964821,"median":-8.461728,"eighty":-6.495967,"marketCap":154118835},{"date":"2024-12-27","current":-6.310352,"twenty":-15.760957,"median":-8.366804,"eighty":-6.403683,"marketCap":144895507},{"date":"2025-01-03","current":-5.856836,"twenty":-15.652229,"median":-8.303377,"eighty":-6.363974,"marketCap":134482072},{"date":"2025-01-10","current":-5.325574,"twenty":-15.570683,"median":-8.28632,"eighty":-6.315537,"marketCap":122283477},{"date":"2025-01-17","current":-6.077115,"twenty":-15.523297,"median":-8.249595,"eighty":-6.288654,"marketCap":139540026},{"date":"2025-01-24","current":-6.517673,"twenty":-15.50282,"median":-8.139601,"eighty":-6.28436,"marketCap":149655935},{"date":"2025-01-31","current":-6.297394,"twenty":-15.473282,"median":-8.073041,"eighty":-6.236001,"marketCap":144597981},{"date":"2025-02-07","current":-7.867,"twenty":-15.425578,"median":-8.088839,"eighty":-6.236001,"marketCap":130062872},{"date":"2025-02-14","current":-7.722981,"twenty":-15.280653,"median":-8.030693,"eighty":-6.247693,"marketCap":127681858},{"date":"2025-02-21","current":-7.038894,"twenty":-15.117652,"median":-7.97035,"eighty":-6.260979,"marketCap":116372043},{"date":"2025-02-28","current":-7.200915,"twenty":-14.922849,"median":-7.899257,"eighty":-6.280067,"marketCap":119050684},{"date":"2025-03-07","current":-7.830995,"twenty":-14.578546,"median":-7.867,"eighty":-6.294726,"marketCap":129467618},{"date":"2025-03-14","current":-8.245048,"twenty":-14.152696,"median":-7.888185,"eighty":-6.298884,"marketCap":136313033},{"date":"2025-03-21","current":-8.209043,"twenty":-13.908059,"median":-7.867,"eighty":-6.302115,"marketCap":135717779},{"date":"2025-03-28","current":-7.110904,"twenty":-13.595467,"median":-7.836063,"eighty":-6.306305,"marketCap":117562550},{"date":"2025-04-04","current":-5.27467,"twenty":-13.332709,"median":-7.821994,"eighty":-6.280067,"marketCap":87204626},{"date":"2025-04-11","current":-4.842615,"twenty":-12.988406,"median":-7.793903,"eighty":-6.226574,"marketCap":80061584},{"date":"2025-04-17","current":-4.464567,"twenty":-12.673549,"median":-7.741272,"eighty":-6.154861,"marketCap":73811424},{"date":"2025-04-25","current":-4.590583,"twenty":-12.555761,"median":-7.674628,"eighty":-6.056383,"marketCap":75894811},{"date":"2025-05-02","current":-4.662592,"twenty":-12.434833,"median":-7.63297,"eighty":-6.012327,"marketCap":77085317},{"date":"2025-05-09","current":-4.48257,"twenty":-12.382378,"median":-7.614926,"eighty":-5.935607,"marketCap":74109050},{"date":"2025-05-16","current":-5.972632,"twenty":-12.227313,"median":-7.558201,"eighty":-5.893196,"marketCap":74406677},{"date":"2025-05-23","current":-5.255916,"twenty":-11.632708,"median":-7.513523,"eighty":-5.862019,"marketCap":65477876},{"date":"2025-05-30","current":-5.017011,"twenty":-11.501318,"median":-7.475136,"eighty":-5.83092,"marketCap":62501609},{"date":"2025-06-06","current":-4.801996,"twenty":-11.15375,"median":-7.4411,"eighty":-5.738446,"marketCap":59822968},{"date":"2025-06-13","current":-4.778106,"twenty":-10.774586,"median":-7.421122,"eighty":-5.634716,"marketCap":59525342},{"date":"2025-06-20","current":-4.204733,"twenty":-10.62292,"median":-7.416943,"eighty":-5.48096,"marketCap":52382300},{"date":"2025-06-27","current":-4.06139,"twenty":-10.489162,"median":-7.344933,"eighty":-5.438999,"marketCap":50596540},{"date":"2025-07-01","current":-2.986316,"twenty":-10.413329,"median":-7.290926,"eighty":-5.407572,"marketCap":37203338}],"updateTime":1751455378107}}}